Food and Drug Administration (FDA) announced that theyve cleared the first generic GLP-1 injectable to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes as an adjunct to diet and exercise. This language likely means that the drug will be available only to diabetics, in contrast to some of the name-brand medications in this class which have been approved for some weight loss cases
However, Clare Thompson, a general practitioner and lead of the weight management service at Cadogan Clinic in the United Kingdom, further noted the studys limitations
GLP-1 receptor agonists such as semaglutide are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2, and should be avoided during pregnancy and breastfeeding
Asia Pacific accounted for the highest revenue share of more than 51% in 2020 and is anticipated to grow at the fastest CAGR of more than 10% over the forecast period
Thank you for your help
They are inspected by the FDA, so they have a higher level of accountability in terms of their manufacturing, sterility testing and authentication of the product, Moore said